Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)
Phase III Clinical Trial
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)